Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain

Current Opinion in Pharmacology

Volumn 12, Issue 1, 2012, Pages 100-108

  Dolly, J Oliver ^a   O'Connell, Marie Ann ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; PLACEBO; RECOMBINANT BOTULINUM TOXIN A; RECOMBINANT BOTULINUM TOXIN E; RECOMBINANT PROTEIN; SNARE PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ALLODYNIA; ANALGESIC ACTIVITY; BRAIN SLICE; CHRONIC PAIN; CHRONIC TENSION HEADACHE; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM BOTULINUM; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSTONIA; ENDOCYTOSIS; ESCHERICHIA COLI; EXOCYTOSIS; HUMAN; HYPERALGESIA; INFLAMMATORY PAIN; MEDIATOR RELEASE; MIGRAINE; MULTICENTER STUDY (TOPIC); NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN ENGINEERING; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TRANSFORMED MIGRAINE; TREATMENT RESPONSE;

ANALGESICS; CHRONIC PAIN; EXOCYTOSIS; HUMANS; NEUROTOXINS;

EID: 84857234795     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.11.001     Document Type: Review

References (70)

1. H. Merskey, and N. Bogduk Classification of Chronic Pain 1994 IASP Press Seattle, WA
2. A. Dray Inflammatory mediators of pain Br J Anaesth 75 1995 125 131
3. C.J. Woolf Pain: moving from symptom control toward mechanism-specific pharmacologic management Ann Intern Med 140 2004 441 451
4. M. Costigan, J. Scholz, and C.J. Woolf Neuropathic pain: a maladaptive response of the nervous system to damage Annu Rev Neurosci 32 2009 1 32
5. A. Latremoliere, and C.J. Woolf Central sensitization: a generator of pain hypersensitivity by central neural plasticity J Pain 10 2009 895 926
6. C.J. Woolf Central sensitization: implications for the diagnosis and treatment of pain Pain 152 2011 S2 S15
7. A.I. Basbaum, D.M. Bautista, G. Scherrer, and D. Julius Cellular and molecular mechanisms of pain Cell 139 2009 267 284
8. M.N. Raftery, K. Sarma, A.W. Murphy, D. De la Harpe, C. Normand, and B.E. McGuire Chronic pain in the Republic of Ireland - community prevalence, psychosocial profile and predictors of pain-related disability: results from the Prevalence, Impact and Cost of Chronic Pain (PRIME) study. Part 1 Pain 152 2011 1096 1103
9. H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment Eur J Pain 10 2006 287 333
10. K.R. Aoki, and J. Francis Updates on the antinociceptive mechanism hypothesis of botulinum toxin A Parkinson Relat Disord 17 Suppl. 1 2011 S28 S33
11. J.O. Dolly, G.W. Lawrence, J. Meng, J. Wang, and S.V. Ovsepian Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics Curr Opin Pharmacol 9 2009 326 335
12. M. Montal Botulinum neurotoxin: a marvel of protein design Annu Rev Biochem 79 2010 591 617
13. J. Meng, J. Wang, G. Lawrence, and J.O. Dolly Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential J Cell Sci 120 2007 2864 2874
14. K.R. Aoki Pharmacology and immunology of botulinum toxin serotypes J Neurol 248 Suppl. 1 2001 3 10
15. P. Roggenkamper, W.H. Jost, K. Bihari, G. Comes, and S. Grafe Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm J Neural Transm 113 2006 303 312
16. W.H. Jost, A. Kohl, S. Brinkmann, and G. Comes Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers J Neural Transm 112 2005 905 913
17. D. Dressler, and R. Eleopra Clinical use of non-A botulinum toxins: botulinum toxin type B Neurotox Res 9 2006 121 125
18. 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis J Cell Biol 103 1986 535 544
19. J.O. Dolly, J. Black, R.S. Williams, and J. Melling Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization Nature 307 1984 457 460
20. B. Poulain, S. Mochida, U. Weller, B. Hogy, E. Habermann, J.D. Wadsworth, C.C. Shone, J.O. Dolly, and L. Tauc Heterologous combinations of heavy and light chains from botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in Aplysia J Biol Chem 266 1991 9580 9585
21. B. Poulain, L. Tauc, E.A. Maisey, J.D. Wadsworth, P.M. Mohan, and J.O. Dolly Neurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chain Proc Natl Acad Sci USA 85 1988 4090 4094
22. + channels probed with botulinum neurotoxins and dendrotoxins J.O. Dolly, Neurotoxins in Neurochemistry 1988 Elis Horwood Limited Chichester, U.K. 77 99
23. H.T. McMahon, P. Foran, J.O. Dolly, M. Verhage, V.M. Wiegant, and D.G. Nicholls Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action J Biol Chem 267 1992 21338 21343
24. M.F. Brin, S. Fahn, C. Moskowitz, A. Friedman, H.M. Shale, P.E. Greene, A. Blitzer, T. List, D. Lange, and R.E. Lovelace Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm Mov Disord 2 1987 237 254
25. W.J. Binder, A. Blitzer, and M.F. Brin Treatment of hyperfunctional lines of the face with botulinum toxin A Dermatol Surg 24 1998 1198 1205
26. L.L. Simpson Molecular pharmacology of botulinum toxin and tetanus toxin Annu Rev Pharmacol Toxicol 26 1986 427 453
27. M. Dong, F. Yeh, W.H. Tepp, C. Dean, E.A. Johnson, R. Janz, and E.R. Chapman SV2 is the protein receptor for botulinum neurotoxin A Science 312 2006 592 596
28. R.W. Bullens, G.M. O'Hanlon, E. Wagner, P.C. Molenaar, K. Furukawa, K. Furukawa, J.J. Plomp, and H.J. Willison Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function J Neurosci 22 2002 6876 6884
29. B.C. Yowler, R.D. Kensinger, and C.L. Schengrund Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I J Biol Chem 277 2002 32815 32819
30. M. Kitamura, K. Takamiya, S. Aizawa, K. Furukawa, and K. Furukawa Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice Biochim Biophys Acta 1441 1999 1 3
31. E. Fernandez-Salas, P. Garay, B. Jacky, J. Dupuy, J. Wang, J. Nelson, C.S. Raymond, and K.R. Aoki Identification of the fibroblast growth factor receptor FGFR3 as a component of the receptor complex for Botulinum Neurotoxin Type A Toxicon 5 Suppl. 1 2008 3
32. M. Dong, H. Liu, W.H. Tepp, E.A. Johnson, R. Janz, and E.R. Chapman Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons Mol Biol Cell 19 2008 5226 5237
33. S. Mahrhold, A. Rummel, H. Bigalke, B. Davletov, and T. Binz The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves FEBS Lett 580 2006 2011 2014
34. T. Nishiki, Y. Tokuyama, Y. Kamata, Y. Nemoto, A. Yoshida, K. Sato, M. Sekiguchi, M. Takahashi, and S. Kozaki The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a FEBS Lett 378 1996 253 257
35. M. Dong, D.A. Richards, M.C. Goodnough, W.H. Tepp, E.A. Johnson, and E.R. Chapman Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells J Cell Biol 162 2003 1293 1303
36. A. Rummel, T. Karnath, T. Henke, H. Bigalke, and T. Binz Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G J Biol Chem 279 2004 30865 30870
37. A. Rummel, T. Eichner, T. Weil, T. Karnath, A. Gutcaits, S. Mahrhold, K. Sandhoff, R.L. Proia, K.R. Acharya, and H. Bigalke Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept Proc Natl Acad Sci USA 104 2007 359 364
38. J. Wang, J. Meng, G.W. Lawrence, T.H. Zurawski, A. Sasse, M.O. Bodeker, M.A. Gilmore, E. Fernandez-Salas, J. Francis, and L.E. Steward Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics J Biol Chem 283 2008 16993 17002
39. G. Lawrence, J. Wang, C.K. Chion, K.R. Aoki, and J.O. Dolly Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E J Pharmacol Exp Ther 320 2007 410 418
40. L.L. Simpson The action of botulinal toxin Rev Infect Dis 1 1979 656 662
41. A. Fischer, and M. Montal Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes Proc Natl Acad Sci USA 104 2007 10447 10452
42. J. Wang, T.H. Zurawski, J. Meng, G. Lawrence, W.M. Olango, D.P. Finn, L. Wheeler, and J.O. Dolly A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic J Biol Chem 286 2011 6375 6385
43. J. Molgo, J.X. Comella, D. Angaut-Petit, M. Pecot-Dechavassine, N. Tabti, L. Faille, A. Mallart, and S. Thesleff Presynaptic actions of botulinal neurotoxins at vertebrate neuromuscular junctions J Physiol (Paris) 84 1990 152 166
44. J. Meng, S.V. Ovsepian, J. Wang, M. Pickering, A. Sasse, K.R. Aoki, G.W. Lawrence, and J.O. Dolly Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential J Neurosci 29 2009 4981 4992
45. P.G. Foran, N. Mohammed, G.O. Lisk, S. Nagwaney, G.W. Lawrence, E. Johnson, L. Smith, K.R. Aoki, and J.O. Dolly Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons J Biol Chem 278 2003 1363 1371
46. J.E. Keller, E.A. Neale, G. Oyler, and M. Adler Persistence of botulinum neurotoxin action in cultured spinal cord cells FEBS Lett 456 1999 137 142
47. M.A. Breidenbach, and A.T. Brunger Substrate recognition strategy for botulinum neurotoxin serotype A Nature 432 2004 925 929
48. D. Dubuisson, and S.G. Dennis The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats Pain 4 1977 161 174
49. H. Wheeler-Aceto, F. Porreca, and A. Cowan The rat paw formalin test: comparison of noxious agents Pain 40 1990 229 238
50. S. Puig, and L.S. Sorkin Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity Pain 64 1996 345 355
51. M. Cui, S. Khanijou, J. Rubino, and K.R. Aoki Subcutaneous administration of botulinum toxin A reduces formalin-induced pain Pain 107 2004 125 133
52. S. Luvisetto, S. Marinelli, F. Lucchetti, F. Marchi, S. Cobianchi, O. Rossetto, C. Montecucco, and F. Pavone Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice Brain Res 1082 2006 124 131
53. J.D. Levine, and N. Alessandri-Haber TRP channels: targets for the relief of pain Biochim Biophys Acta 1772 2007 989 1003
54. L. Bach-Rojecky, and Z. Lackovic Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain Croat Med J 46 2005 201 208
55. K.R. Aoki Evidence for antinociceptive activity of botulinum toxin type A in pain management Headache 43 Suppl. 1 2003 S9 S15
56. K.R. Aoki Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A Neurotoxicology 26 2005 785 793
57. S. Marinelli, S. Luvisetto, S. Cobianchi, W. Makuch, I. Obara, E. Mezzaroma, M. Caruso, E. Straface, B. Przewlocka, and F. Pavone Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models Neuroscience 171 2010 316 328
58. H.J. Park, Y. Lee, J. Lee, C. Park, and D.E. Moon The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain Can J Anaesth 53 2006 470 477
59. L. Bach-Rojecky, M. Relja, and Z. Lackovic Botulinum toxin type A in experimental neuropathic pain J Neural Transm 112 2005 215 219
60. L. Bach-Rojecky, M. Salkovic-Petrisic, and Z. Lackovic Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection Eur J Pharmacol 633 2010 10 14
61. N. Barrientos, and P. Chana Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study J Headache Pain 4 2003 146 151
62. M. Relja, and S. Telarovic Botulinum toxin in tension-type headache J Neurol 251 Suppl. 1 2004 I12 I14
63. D. Ranoux, N. Attal, F. Morain, and D. Bouhassira Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain Ann Neurol 64 2008 274 283
64. D. Miller, D. Richardson, M. Eisa, R.J. Bajwa, and B. Jabbari Botulinum neurotoxin-A for treatment of refractory neck pain: a randomized, double-blind study Pain Med 10 2009 1012 1017
65. D.W. Dodick, C.C. Turkel, R.E. DeGryse, S.K. Aurora, S.D. Silberstein, R.B. Lipton, H.C. Diener, and M.F. Brin OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program Headache 50 2010 921 936
66. J.O. Dolly, J. Wang, T.H. Zurawski, and J. Meng Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators FEBS J 278 2011 4454 4466
67. J.D. Wadsworth, M. Desai, H.S. Tranter, H.J. King, P. Hambleton, J. Melling, J.O. Dolly, and C.C. Shone Botulinum type F neurotoxin. Large-scale purification and characterization of its binding to rat cerebrocortical synaptosomes Biochem J 268 1990 123 128
68. V.B. O'Leary, S.V. Ovsepian, A. Raghunath, Q. Huo, G.W. Lawrence, L. Smith, and J.O. Dolly Innocuous full-length botulinum neurotoxin targets and promotes the expression of lentiviral vectors in central and autonomic neurons Gene Ther 18 2011 656 665
69. H.G. Gassner, A.E. Brissett, C.C. Otley, D.K. Boahene, A.J. Boggust, A.L. Weaver, and D.A. Sherris Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study Mayo Clin Proc 81 2006 1023 1028
70. J.A. Kauffman, J.F. Way Jr., L.S. Siegel, and L.C. Sellin Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction Toxicol Appl Pharmacol 79 1985 211 217